The driver may be mast-cell-mediated or systemic rather than NF-B-local, and if so, increasing the dose for additional KPV will not address it see the mast-cell note under Phenotype Considerations
This is why subcutaneous injection remains the primary clinical delivery route, a point that has direct implications for the dosage chart below
Enhanced Bioavailability and Systemic Reach Injecting BPC-157 directly into subcutaneous tissue ensures high bioavailability , avoiding enzymatic degradation
That said, the combination has not been tested for safety or effect in a human trial, so "can" here means chemically formulated together, not clinically validated
If you do not intend to use the entire vial within this timeframe, divide the reconstituted solution into smaller, single-use aliquots and freeze them at -20C